Two leading oncology groups will receive $5 million from the Australian Brain Cancer Mission to undertake 5 year programs designed to improve outcomes for children and adults with brain cancer.
The Australian and New Zealand Children’s Haematology Oncology Group (ANZCHOG) and Cooperative Trials Group for Neuro-Oncology (COGNO), will each receive $2.5 million to improve access, and raise participation in international trials.
The funding will enable ANZCHOG to open 5 high quality, international brain cancer clinical trials, with a target of 90% of eligible children with brain cancer enrolling in these trials. COGNO will be funded under the Australian Brain Cancer Mission to expedite start-up of international trials in Australia and increase recruitment by up to 25% in these trials for adults with brain cancer.
For more information: